Healthcare Industry News: GSK
News Release - November 2, 2012
Vical Names Mammen P. Mammen, Jr., M.D., Vice President, Clinical VaccinesSAN DIEGO, Nov. 2, 2012 -- (Healthcare Sales & Marketing Network) -- Vical Incorporated (VICL) today announced the appointment of Mammen P. "Anza" Mammen, Jr., M.D., as Vice President, Clinical Vaccines. Prior to joining Vical, Dr. Mammen completed a 21-year career in the Army's Medical Corps, retiring as a colonel and recipient of the Legion of Merit. His experiences have spanned the areas of clinical medicine, infectious disease research, medical diplomacy, clinical trials, vaccine program management, and public health.
"Anza brings a wealth of infectious disease vaccine knowledge to Vical's management team, including extensive experience in infectious disease research and vaccine trials," said Vijay B. Samant, Vical's President and Chief Executive Officer. "His demonstrated expertise in clinical program management supplements Vical's existing strengths and provides focused support for our pipeline of vaccine development programs."
Most recently, he served as Infectious Disease Consultant and Chief, Pandemic Warning Team, U.S. Department of Defense, Fort Detrick, Maryland. From 2006 to 2010, he served as the Army's Product Manager for vaccines in Advanced Development against dengue, hepatitis E, and HIV viruses for the U.S. Army Medical Research and Materiel Command (USAMRMC), Fort Detrick, Maryland. As Chief, Department of Virology, the Armed Forces Research Institute of Medical Sciences (AFRIMS), Thailand, from 2001 to 2006, Dr. Mammen contributed to a number of the Army's U.S. Food and Drug Administration (FDA)-regulated vaccine studies. He was Principal Investigator of an infant trial to evaluate the safety and immunogenicity of the Army's live-attenuated dengue vaccine in Thailand, in collaboration with GlaxoSmithKline Biologicals (GSK), published in the American Journal of Tropical Medicine and Hygiene. He was Project Director for an efficacy trial in Nepal of a recombinant hepatitis E vaccine, conducted in collaboration with GSK, published in The New England Journal of Medicine. His previous assignments include serving as Infectious Disease Officer, Department of Virus Diseases, the Walter Reed Army Institute of Research (WRAIR), and Chief, Internal Medicine Clinic, 121st General Hospital, Seoul, South Korea.
Dr. Mammen received his M.D. degree from the Pennsylvania State University College of Medicine and is Board-certified in Infectious Diseases. He has been elected as Fellow by the Infectious Disease Society of America (IDSA) and the American College of Physicians (ACP). He received his Internal Medicine and Infectious Disease clinical training from the Walter Reed Army Medical Center and audited the Medical Research Fellowship at WRAIR. He earned a B.A. degree in mathematics from Williams College. Dr. Mammen has authored or co-authored nearly 50 scientific publications spanning multiple emerging and re-emerging infectious diseases.
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Vical's pipeline of vaccine development programs and the related future contributions of Dr. Mammen. Actual results set forth in or implied by these forward-looking statements may differ materially as a result of various risks and uncertainties. These risks and uncertainties include whether Vical or others will continue development of any product candidates; whether any product candidates will be successfully developed, approved or commercialized; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Source: Vical Inc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.